tetano
Editor, Senior Moderator
BMC Infect Dis
. 2023 Jan 6;23(1):7.
doi: 10.1186/s12879-022-07973-4.
COVID arm as a common cutaneous manifestation after mRNA-1273 vaccination: a systematic review
Maulidina Agustin[SUP] 1 [/SUP], Monica Trifitriana[SUP] 2 [/SUP], Retno Danarti[SUP] 3 4 [/SUP]
Affiliations
Abstract
Background: By August 2022, CoronaVirus Disease-2019 (COVID-19) had caused 600 million illnesses and 6.5 million fatalities globally. A massive vaccination program is being implemented worldwide to suppress this condition. Several works of literature stated that mRNA COVID-19 vaccination, specifically with the mRNA-1273 vaccine, is followed by clear evidence of the COVID arm effects associated with this vaccine.
Objective: To analyze the latest evidence of COVID arm as a common effect of mRNA-1273 vaccination with the ultimate goal of improving vaccine counseling to help healthcare professionals and reassure patients.
Methods: A comprehensive search was performed on topics that assess the COVID arm as a cutaneous manifestation following mRNA-1273 vaccination from inception up until July 2022.
Results: Eighteen studies with a total of 1129 participants after the first and second dose of mRNA-1273 vaccination reported that most participants had COVID arm following the first dose administration. The characteristics of the patients were a mean age of 43.8 years old, and females represented ≥ 50% in most studies, with a mean onset of 6.9 days after the first dose administration. Symptoms resolved within seven days following the treatment and were harmless.
Conclusions: This study found that the COVID arm condition is most common following the first mRNA-1273 vaccination in the female and middle-aged group. The correlation between demographic variables and COVID arm risk elucidates that the reaction is a type IV allergic skin reaction.
Keywords: COVID arm; Cutaneous manifestation; SARS-CoV-2; Skin rash; Vaccination; mRNA-1273.
. 2023 Jan 6;23(1):7.
doi: 10.1186/s12879-022-07973-4.
COVID arm as a common cutaneous manifestation after mRNA-1273 vaccination: a systematic review
Maulidina Agustin[SUP] 1 [/SUP], Monica Trifitriana[SUP] 2 [/SUP], Retno Danarti[SUP] 3 4 [/SUP]
Affiliations
- PMID: 36609222
- DOI: 10.1186/s12879-022-07973-4
Abstract
Background: By August 2022, CoronaVirus Disease-2019 (COVID-19) had caused 600 million illnesses and 6.5 million fatalities globally. A massive vaccination program is being implemented worldwide to suppress this condition. Several works of literature stated that mRNA COVID-19 vaccination, specifically with the mRNA-1273 vaccine, is followed by clear evidence of the COVID arm effects associated with this vaccine.
Objective: To analyze the latest evidence of COVID arm as a common effect of mRNA-1273 vaccination with the ultimate goal of improving vaccine counseling to help healthcare professionals and reassure patients.
Methods: A comprehensive search was performed on topics that assess the COVID arm as a cutaneous manifestation following mRNA-1273 vaccination from inception up until July 2022.
Results: Eighteen studies with a total of 1129 participants after the first and second dose of mRNA-1273 vaccination reported that most participants had COVID arm following the first dose administration. The characteristics of the patients were a mean age of 43.8 years old, and females represented ≥ 50% in most studies, with a mean onset of 6.9 days after the first dose administration. Symptoms resolved within seven days following the treatment and were harmless.
Conclusions: This study found that the COVID arm condition is most common following the first mRNA-1273 vaccination in the female and middle-aged group. The correlation between demographic variables and COVID arm risk elucidates that the reaction is a type IV allergic skin reaction.
Keywords: COVID arm; Cutaneous manifestation; SARS-CoV-2; Skin rash; Vaccination; mRNA-1273.